Advertisement.
Advertisement.
Advertisement
Advertisement.
HEPA Hepion Pharmaceuticals Inc
27,340
| Market Cap | $4.41M |
| Volume | 93,431.00 |
| 52-Wk High | $8.31 |
| 52-Wk Low | $0.7301 |
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Benzinga•4 days ago
Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson's disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans...
Share to Feed
An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...
TipRanks Financial Blog•4 days ago
Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
read more...
Benzinga•3 months ago
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
Globe Newswire•5 months ago
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Globe Newswire•5 months ago
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic...
Globe Newswire•7 months ago